ArticleVeterinary research communications2025
Development and application of a novel indirect ELISA based on recombinant ORFV114 protein for serodiagnosis of Orf virus in goats.
Article in Veterinary research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Host-Orf virus interactions: A comprehensive review of pathogenesis and immune evasion mechanisms.Virulence · 2026Review
- A novel duplex TaqMan qPCR assay for rapid differential diagnosis and co-infection screening of Orf virus and Brucella spp. in goats.Veterinary research communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Orf, resulting from infection with the Orf virus (ORFV), is a zoonotic disease that threatens the health of both animals and people. Reliable serological detection methods are critical for managing and preventing Orf outbreaks. The ORFV114 protein, highly conserved across ORFV strains, serves as a promising antigen for diagnostic applications. In this study, we developed a novel indirect ELISA for ORFV serodiagnosis using a recombinant ORFV114 protein. The antigen was produced in Escherichia coli via the pET-32a-ORFV114 plasmid, then purified and refolded for use in the assay. Receiver operating characteristic (ROC) analysis of sera from 40 ORFV-negative and 30 ORFV-positive goats established an optimal cut-off value of 0.2938. At this threshold, the assay achieved a diagnostic sensitivity of 93.33% and a specificity of 95%, with an excellent area under the curve (AUC) of 0.9871 (P < 0.0001). The ELISA demonstrated high specificity, with no cross-reactivity against FMDV, GTPV, or PPRV, and showed good reproducibility (CV < 10%). Testing 168 serum samples from asymptomatic goats with the assay showed a 16.67% seropositivity rate for ORFV and an approximate 93.45% concordance with the virus neutralization test, demonstrating its practical applicability. This newly established indirect ELISA assay is a sensitive and specific tool for ORFV surveillance.
Indexed as
Identifiers
40996615What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.